Management of clozapine-related hepatotoxicity

Journal of Clinical Psychopharmacology

Volumn 29, Issue 6, 2009, Pages 606-607

  Keane, Sarah ^a   Lane, Abbie ^a,b   Larkin, Terence ^a   Clarke, Mary ^a,b  

^a St John of God Hospitaller Services Ireland   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LITHIUM; OLANZAPINE; RISPERIDONE; THIORIDAZINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUDITORY HALLUCINATION; BEDTIME DOSAGE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HUMAN; LETTER; LIVER FUNCTION TEST; LIVER TOXICITY; MORNING DOSAGE; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; PROVOCATION TEST; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SIDE EFFECT;

ADULT; CLOZAPINE; DISEASE MANAGEMENT; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; MIDDLE AGED;

EID: 72949088911     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181c163ef     Document Type: Letter

References (13)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
2. Narendran R, Young CM, Pristach CA, et al. Efficacy of clozapine in the treatment of atypical antipsychotic refractory schizophrenia: a pilot study. J Clin Psychopharmacol. 2003;23:103-104.
3. Macfarlane B, Davies S, Mannan K, et al. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology. 1997;112:1707-1709.
4. Hummer M, Kurz M, Kurzthaler I, et al. Hepatotoxicity of clozapine. J Clin Psychopharmacol. 1997;17:314-317.
5. Medicines and Healthcare Products Regulatory Agency [Online]. Available at: www.mhra.gov.uk/onlineservices/medicines/ DrugAnalysisPrints/Clozaril. Accessed August 15, 2008.
6. Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines. 9th ed. London, UK: Informa Healthcare; 2007;87.
7. North-Lewis P, ed. Drugs and the Liver: A Guide to Drug Handling in Liver Dysfunction. 1st ed. London, UK: Pharmaceutical Press; 2008:59-60.
8. Wagstaff AJ, Bryson HM. Clozapine: a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs. 1995;4:370-400.
9. Gareri P, De Fazio P, Russo E, et al. The safety of clozapine in the elderly. Expert Opin Drug Saf. 2008;7:525-538.
10. Gaertner HJ, Fischer E, Hoss J. Side effects of clozapine. Psychopharmacology. 1989; 99:S97YS100.
11. Erdogan A, Kocabasoglu N, Yalug I, et al. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature. Int J Psychiatry Med. 2004;34:83-89.
12. Marinkovic D, Timotijevic I, Babinski T, et al. The side-effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:537-544.
13. Gaertner I, Altendorf K, Batra A, et al. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J Clin Psychopharmacol. 2001;21:215-222.